Viewing Study NCT01142557


Ignite Creation Date: 2025-12-24 @ 6:50 PM
Ignite Modification Date: 2025-12-27 @ 1:01 PM
Study NCT ID: NCT01142557
Status: COMPLETED
Last Update Posted: 2014-07-11
First Post: 2010-06-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
Sponsor: Merck KGaA, Darmstadt, Germany
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module